These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 24531787)

  • 1. Prognostic value of a cell cycle progression score for men with prostate cancer.
    Cuzick J
    Recent Results Cancer Res; 2014; 202():133-40. PubMed ID: 24531787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort.
    Cooperberg MR; Simko JP; Cowan JE; Reid JE; Djalilvand A; Bhatnagar S; Gutin A; Lanchbury JS; Swanson GP; Stone S; Carroll PR
    J Clin Oncol; 2013 Apr; 31(11):1428-34. PubMed ID: 23460710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance.
    Tosoian JJ; Chappidi MR; Bishoff JT; Freedland SJ; Reid J; Brawer M; Stone S; Schlomm T; Ross AE
    BJU Int; 2017 Dec; 120(6):808-814. PubMed ID: 28481440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score.
    Epstein JI; Zelefsky MJ; Sjoberg DD; Nelson JB; Egevad L; Magi-Galluzzi C; Vickers AJ; Parwani AV; Reuter VE; Fine SW; Eastham JA; Wiklund P; Han M; Reddy CA; Ciezki JP; Nyberg T; Klein EA
    Eur Urol; 2016 Mar; 69(3):428-35. PubMed ID: 26166626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of primary Gleason pattern in Japanese men with Gleason score 7 prostate cancer treated with radical prostatectomy.
    Miyake H; Muramaki M; Furukawa J; Tanaka H; Inoue TA; Fujisawa M
    Urol Oncol; 2013 Nov; 31(8):1511-6. PubMed ID: 22658882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.
    Cuzick J; Swanson GP; Fisher G; Brothman AR; Berney DM; Reid JE; Mesher D; Speights VO; Stankiewicz E; Foster CS; Møller H; Scardino P; Warren JD; Park J; Younus A; Flake DD; Wagner S; Gutin A; Lanchbury JS; Stone S;
    Lancet Oncol; 2011 Mar; 12(3):245-55. PubMed ID: 21310658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy.
    Freedland SJ; Gerber L; Reid J; Welbourn W; Tikishvili E; Park J; Younus A; Gutin A; Sangale Z; Lanchbury JS; Salama JK; Stone S
    Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):848-53. PubMed ID: 23755923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell cycle progression score improves risk stratification in prostate cancer patients with adverse pathology after radical prostatectomy.
    Shangguan X; Qian H; Jiang Z; Xin Z; Pan J; Dong B; Xue W
    J Cancer Res Clin Oncol; 2020 Mar; 146(3):687-694. PubMed ID: 31745702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence.
    Koch MO; Cho JS; Kaimakliotis HZ; Cheng L; Sangale Z; Brawer M; Welbourn W; Reid J; Stone S
    Cancer Biomark; 2016 Jun; 17(1):83-8. PubMed ID: 27314296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort.
    Cuzick J; Berney DM; Fisher G; Mesher D; Møller H; Reid JE; Perry M; Park J; Younus A; Gutin A; Foster CS; Scardino P; Lanchbury JS; Stone S;
    Br J Cancer; 2012 Mar; 106(6):1095-9. PubMed ID: 22361632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Gleason pattern 5 including tertiary pattern 5 on outcomes of salvage treatment for biochemical recurrence in pT2-3N0M0 prostate cancer.
    Taguchi S; Shiraishi K; Fukuhara H; Nakagawa K; Morikawa T; Naito A; Kakutani S; Takeshima Y; Miyazaki H; Nakagawa T; Fujimura T; Kume H; Homma Y
    Int J Clin Oncol; 2016 Oct; 21(5):975-980. PubMed ID: 27098807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic capabilities and clinical utility of cell cycle progression testing, prostate imaging reporting and data system, version 2, and clinicopathologic data in management of localized prostate cancer.
    Morris DS; Woods JS; Edwards B; Lenz L; Logan J; Flake DD; Mabey B; Bishoff JT; Cohen T; Stone S
    Urol Oncol; 2021 Jun; 39(6):366.e19-366.e28. PubMed ID: 33257218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of a cell-cycle progression score in men with prostate cancer managed with active surveillance after MRI-guided prostate biopsy--a pilot study.
    Arsov C; Jankowiak F; Hiester A; Rabenalt R; Quentin M; Schimmöller L; Blondin D; Antoch G; Albers P
    Anticancer Res; 2014 May; 34(5):2459-66. PubMed ID: 24778061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors after salvage radiotherapy alone in patients with biochemical recurrence after radical prostatectomy.
    Song W; Jeon HG; Sung HH; Jeong BC; Seo SI; Jeon SS; Choi HY; Lee HM
    Int J Urol; 2016 Jan; 23(1):56-61. PubMed ID: 26502086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy.
    Savdie R; Horvath LG; Benito RP; Rasiah KK; Haynes AM; Chatfield M; Stricker PD; Turner JJ; Delprado W; Henshall SM; Sutherland RL; Kench JG
    BJU Int; 2012 Jun; 109(12):1794-800. PubMed ID: 21992536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
    Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
    Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
    BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.